title: A phase 1 dose-escalation study of XmAb® 2513 in patients with relapsed or refractory Hodgkin lymphoma.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
authors.forename: Anita
authors.initials: A
authors.lastname: Kumar
authors.forename: Kristie A
authors.initials: KA
authors.lastname: Blum
authors.forename: Henry C
authors.initials: HC
authors.lastname: Fung
authors.forename: Mitchell R
authors.initials: MR
authors.lastname: Smith
authors.forename: Paul A
authors.initials: PA
authors.lastname: Foster
authors.forename: Anas
authors.initials: A
authors.lastname: Younes
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C000597571:XMAB-2513
keywords: Hodgkin lymphoma; clinical trials; immunotherapy; monoclonal antibodies; therapy